What is Transgene?
Transgene is a biotechnology firm specializing in the design and development of innovative immunotherapies aimed at treating cancer. The company's product pipeline features personalized therapeutic vaccines, such as TG4050, oncolytic viruses derived from its Invir.IO platform, and advanced technologies like myvac. By integrating cutting-edge genetic engineering with artificial intelligence, Transgene seeks to enhance the efficacy of cancer treatments, focusing on personalized medicine to improve patient outcomes across various cancer types.
How much funding has Transgene raised?
Transgene has raised a total of $144M across 2 funding rounds:
Debt
$22.4M
Stock/Share Issuance
$121.6M
Debt (2016): $22.4M with participation from European Investment Bank
Stock/Share Issuance (2025): $121.6M led by Dassault Group
Key Investors in Transgene
European Investment Bank
The European Investment Bank (EIB) is the European Union's long-term lending institution, established in 1958 and headquartered in Luxembourg. It focuses on financing projects that support EU policy objectives.
Dassault Group
Dassault Group is a French industrial conglomerate founded in 1929, with core businesses in aerospace manufacturing and technology solutions. The group is known for its significant contributions to aviation and software development.
What's next for Transgene?
The recent major strategic investment positions Transgene for accelerated growth and further development of its novel immunotherapy platforms. This backing is likely to fuel advancements in clinical trials, expand research and development capabilities, and potentially forge new strategic partnerships. The company's focus on personalized medicine and leveraging AI suggests a forward-looking approach to oncology, aiming to solidify its market position and deliver impactful therapeutic solutions.
See full Transgene company page
